{"filing":{"accession_number":"0001129928-26-000043","cik":"0001129928","ticker":"ONCY","company_name":"ONCOLYTICS BIOTECH INC","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"oncy-20260713.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000043/oncy-20260713.htm"},"events":[{"id":17528,"run_id":15702,"accession_number":"0001129928-26-000043","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces clinical and regulatory progress on the REO 033 trial, including activation of clinical sites, pre-identification of patients, and a planned Type D FDA meeting to discuss a registrational pathway expansion (Part B). This is a material operational and strategic milestone for a clinical-stage biotech company advancing its lead candidate toward potential registration, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The regulatory milestone and trial expansion represent significant operational progress affecting investor assessment of development timelines and commercial prospects.","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16032,"accession_number":"0001129928-26-000043","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical and regulatory progress on the REO 033 trial, including activation of clinical sites, pre-identification of patients, and a planned Type D FDA meeting to discuss a registrational pathway expansion (Part B). This is a material operational and strategic milestone for a clinical-stage biotech company advancing its lead candidate toward potential registration, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The regulatory milestone and trial expansion represent significant operational progress affecting investor assessment of development timelines and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T13:04:38.961753+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16032,"accession_number":"0001129928-26-000043","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical and regulatory progress on the REO 033 trial, including activation of clinical sites, pre-identification of patients, and a planned Type D FDA meeting to discuss a registrational pathway expansion (Part B). This is a material operational and strategic milestone for a clinical-stage biotech company advancing its lead candidate toward potential registration, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. The regulatory milestone and trial expansion represent significant operational progress affecting investor assessment of development timelines and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T13:04:38.961753+00:00","company_name":"ONCOLYTICS BIOTECH INC","ticker":"ONCY","filing_date":"2026-07-13"}]}